Every box carries a batch number. Look it up and you get the analytical data for the exact vials you received.
Batch lookup →LY3298176, dual GIP/GLP-1 receptor agonist
A unimolecular dual agonist of the GIP and GLP-1 receptors, and the compound behind the SURMOUNT and SURPASS trial programmes.
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a single molecule that activates both the GIP and GLP-1 receptors, with a C20 fatty diacid moiety conferring once-weekly pharmacokinetics. The SURMOUNT-1 trial reported substantial and sustained weight reduction over 72 weeks in participants with obesity, and three-year data in participants with obesity and prediabetes reported markedly lower progression to type 2 diabetes versus placebo. Gastrointestinal adverse events were the most common finding and were generally mild-to-moderate and transient.
Prices in USD per sealed box of 10 vials. Bulk pricing available from 10 boxes — see wholesale.
| Vial strength | Box | Price | |
|---|---|---|---|
| 2mg | 10 vials |
$75.60
$7.56 per vial
|
Order 2mg |
| 5mg | 10 vials |
$46
$4.60 per vial
|
Order 5mg |
| 10mg | 10 vials |
$66
$6.60 per vial
|
Order 10mg |
| 15mg | 10 vials |
$78
$7.80 per vial
|
Order 15mg |
| 20mg | 10 vials |
$93
$9.30 per vial
|
Order 20mg |
| 30mg | 10 vials |
$118
$11.80 per vial
|
Order 30mg |
| 40mg | 10 vials |
$148
$14.80 per vial
|
Order 40mg |
| 50mg | 10 vials |
$163
$16.30 per vial
|
Order 50mg |
| 60mg | 10 vials |
$208
$20.80 per vial
|
Order 60mg |
| 80mg | 10 vials |
$621.60
$62.16 per vial
|
Order 80mg |
| 100mg | 10 vials |
$705.60
$70.56 per vial
|
Order 100mg |
Links open peer-reviewed sources on PubMed. These are provided so you can read the primary literature yourself. Citing a study is not a claim that this compound is safe or effective for any use in humans.
LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
TH9507, trans-3-hexenoyl-GHRH(1-44)
A stabilised GHRH(1-44) analog and the only GH-axis compound with regulatory approval specifically for reducing visceral adipose tissue.
A small-molecule NNMT inhibitor studied in adipocyte metabolism and NAD+ salvage research.
This website sells laboratory research chemicals. Everything on it is intended for qualified researchers and is not for human or veterinary consumption.
We are sorry — you must be at least 21 years old to view this site. Please close this window.
By entering you confirm you are at least 21 years of age, that you will use all products for laboratory research purposes only, and that you accept our Terms of Sale, Privacy Policy and Research Disclaimer.
